RLAY

Insider Trades

Name	Value	Action	Price	Current Price
Catinazzo ThomasChief Financial Officer $228k17.7k shares SellMay 14, 2026 $12.86 --
Bergstrom Donald APresident, R&D $22k1.5k shares SellApr 28, 2026 $14.79 --
Catinazzo ThomasChief Financial Officer $14k972 shares SellApr 28, 2026 $14.79 --
Rahmer PeterSee Remarks $11k753 shares SellApr 28, 2026 $14.79 --
Catinazzo ThomasChief Financial Officer $27k1.8k shares SellApr 9, 2026 $15.00 --
Catinazzo ThomasChief Financial Officer $230k17.7k shares SellApr 7, 2026 $13.01 --

News

seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

globenewswire.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in Juneglobenewswire.comMay 27

fool.comIs Relay Therapeutics a Buy After Promising Trial Results?fool.comMay 22

globenewswire.comRelay Therapeutics Announces Pricing of Public Offering of Common Stockglobenewswire.comMay 20

Trade RLAY

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

CEO: Sanjiv K. Patel
IPO Date: Jul 16, 2020

Market Data

Open: $15.99
High: $16.39
Low: $15.82
Volume: 7.5M
Avg Volume: 3.9M
52W High: $17.47
52W Low: $3.03

Valuation

Market Cap: $2.8B
Enterprise Value: $2.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-236M
Revenue: $15M
Net Income: $-276M
Cash: $84M
Debt: $32M

Events

EarningsAug 6

EPS est. -0.41